Will the European Commission approve Eli Lilly's Foundayo by 15 December 2026?
Posted 2026-10-16 — 60 days before the deadline, stated before the outcome.
Eli Lilly is a pharmaceutical company developing orforglipron, a once-daily oral medication for weight management. The European Commission is the executive body of the European Union responsible for adopting regulatory decisions based on scientific opinions from the Committee for Medicinal Products for Human Use.
The claim
By 2026-12-15, the European Commission has formally adopted the implementing decision approving Eli Lilly's once-daily weight-loss pill Foundayo (orforglipron) for the EU market, following the CHMP positive opinion.
Reasoning trace
- Parallel: EMA CHMP positive opinion for Lilly's Mounjaro (2022), sim=9
- Mapping: Same actor and decision process: CHMP positive opinion is followed by final European Commission approval within a short period, so the Commission's decisive approval is expected within the window.
Evidence so far
5 confirming · 0 denying signals · 3 verified · 1 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 2 times since mint (last on 2026-10-17) — 78% at mint → 84% today.
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.